ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 08:20PM GMT
Release Date Price: $25.62 (-0.16%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have the ACADIA team here with us today. So we have Steve Davis, CEO; and Michael Yang, Chief Commercial Officer. And with that -- thanks for joining us.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So you recently completed 2 campaigns for NUPLAZID, the first being disease awareness and then a second DTC campaign. What is -- maybe you could just walk us through the feedback post these events and provide some color on the impact you've had on NUPLAZID's prescribing activity and sales.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Yes, great. I'm going to give just a really quick lead and let Michael take the question. So what Salveen is referring to is in late 2017, we launched a disease awareness, DTC campaign, to try to fill a gap that Michael will describe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot